行业报告RigelPharmaceuticals2023年第一季度报告1684136094_市.docx
《行业报告RigelPharmaceuticals2023年第一季度报告1684136094_市.docx》由会员分享,可在线阅读,更多相关《行业报告RigelPharmaceuticals2023年第一季度报告1684136094_市.docx(9页珍藏版)》请在第一文库网上搜索。
1、May2,2023/二一、rge1Rige1ReportsFirstQuarter2023Financia1Resu1tsandProvidesBusinessUpdate Firstquarter2023Tota1Revenueof$26.1mi11ionwhichinc1udesTAVA1ISSEnetproductsa1esof$22.3mi11ionandREZ1IDHIAnetproductsa1esof$1.5mi11ion G1oba1expansionofTAVA1ISSEinITPwithJapanese1aunchbypartnerKissei Conferenceca11
2、andwebcastschedu1edtodayat4:30p.m.EasternTimeSOUTHSANFRANCISCO,Ca1if.,May2,2023/PRNewswire/-Rige1Pharmaceutica1s,Inc.(Nasdaq:RIG1)todayreportedfinancia1resu1tsforthefirstquarterendedMarch31,2023,inc1udingsa1esofTAVA1ISSE(fostamatinibdisodiumhexahydrate)tab1etsforthetreatmentofadu1tswithchronicimmune
3、thrombocytopenia(ITP)whohavehadaninsufficientresponsetoaprevioustreatmentandsa1esofREZ1IDHIA(O1utasidenib)capsu1esforthetreatmentofadu1tpatientswithre1apsedorrefractory(RR)acutemye1oid1eukemia(AM1)withasusceptib1eisocitratedehydrogenase-1(IDH1)mutationasdetectedbyanFDA-approvedtest.,Wearethri11edwit
4、hourstrongfirstquarternetproductsa1esperformance,a47%increasefromQ12023.Thisref1ectsourabi1itytoadvanceour1aunchofREZ1IDHIAinm1DH1R/RAM1whi1edrivingcontinuedgrowthinTAVA1ISSEITPsa1es,saidRau1Rodriguez,RigespresidentandCEO.Tortheremainderof2023,wehaveestab1ishedastrongfoundationforourhemato1ogy-onco1
5、ogybusinesstosuccessfu11yde1ivergrowthinbothTAVA1ISSEandREZ1IDHIA,andtoadvanceourdeve1opmentprograms.11BUSineSSUPdate Inthefirstquarterof2023,atota1of2,281bott1esofTAVA1ISSEwereso1dintheU.S.,2,256ofwhichwereshippeddirect1ytopatientsandc1inics,representingthehighestnumberofbott1esshippedtopatientsand
6、c1inicsinaquartersince1aunch. Duringthefirstfu11quarterof1aunch,atota1of113bott1esofREZ1IDHIAwereso1dintheU.S.,109ofwhichwereshippeddirect1ytopatientsandc1inics. REZ1IDHIAwasaddedbytheNationa1ComprehensiveCancerNetwork(NCCN)tothe1atestNCCNC1inica1PracticeGuide1inesinOnco1ogy(NCCNGuide1ines)forAM1inJ
7、anuary2023.REZ1IDHIAisinc1udedasarecommendedtargetedtherapyforadu1tpatientswithR/RAM1withIDH1mutation. Rige1announcedapeer-reviewedpub1icationofdatainB1oodAdvancesinFebruary2023,whichsummarizedc1inica1resu1tsfromthePhase2registrationtria1ofREZ1IDHIAinpatientsWithm1DH1R/RAM1.Thepub1isheddatademonstra
8、tethatREZ1IDHIAinduceddurab1eremissionsandtransfusionindependencewithawe11-characterizedsafetyprofi1e. InApri1,RigespartnerKisseiannouncedthe1aunchofTAVA1ISSEinJapanforthetreatmentofchronicITP. Rige1continuestoadvancetheopen-1abe1,Phase1bc1inica1tria1ofR289,aninvestigationa1,potent,andse1ectiveIRAK1
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 行业 报告 RigelPharmaceuticals2023 第一 季度 1684136094
链接地址:https://www.001doc.com/doc/581488.html